hero-faq

Answering your frequently asked questions

Get the information you need about the Oncoguard® Liver solution

exs-lvr-Icon-Test-TubesAbout the Oncoguard® Liver test

exs-lvr-Icon-Report-NegativeResults

exs-lvr-Icon-EffectiveFrequency

exs-lvr-Icon-BillingInsurance & Billing

exs-lvr-CustomerService-305701484
If you have other questions about the Oncoguard® Liver solution, please ask your doctor or call us at 1-844-870-8870.

The term liver cancer is used to represent the most common form of liver cancer, hepatocellular carcinoma (HCC).

References: 1. Mayo Clinic Staff. Abdominal ultrasound https://www.mayoclinic.org/tests-procedures/abdominal-ultrasound/about/pac-20392738. Accessed April 18, 2024. 2. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. 3. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021) 4. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. The New England Journal of Medicine. 2014;370(14):1287-1297.5. Habib ZA. Maternal serum alpha-feto-protein: its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand Suppl. 1977;61:1-92.